{"id":"aprepitant-plus-ondansetron","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hiccups"}]},"_chembl":{"chemblId":"CHEMBL1201111","moleculeType":"Small molecule","molecularWeight":"329.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprepitant is a selective antagonist of human substance P/neurokinin-1 receptors, which are involved in the central control of emesis, particularly delayed nausea and vomiting. Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. The combination targets complementary pathways to provide broader and more effective antiemetic coverage than either agent alone.","oneSentence":"Aprepitant blocks neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone while ondansetron blocks serotonin 5-HT3 receptors, together providing dual antiemetic coverage against chemotherapy-induced nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:30.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"},{"name":"Postoperative nausea and vomiting (PONV) prevention"}]},"trialDetails":[{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT06007586","phase":"PHASE3","title":"Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2024-05-31","conditions":"Gynecological Tumor, Ovarian Cancer, Cervical Cancer","enrollment":143},{"nctId":"NCT04606264","phase":"PHASE3","title":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","status":"COMPLETED","sponsor":"Jennifer Holder-Murray","startDate":"2023-05-15","conditions":"Perioperative Optimization","enrollment":2977},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05189756","phase":"PHASE4","title":"Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-03-17","conditions":"Postoperative Nausea and Vomiting, Bariatric Surgery","enrollment":71},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT06697782","phase":"PHASE4","title":"Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-07-01","conditions":"Thyroid Cancer","enrollment":600},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT06080880","phase":"NA","title":"Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2023-12-01","conditions":"Nausea With Vomiting Chemotherapy-Induced","enrollment":98},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT03237611","phase":"PHASE2","title":"Low Dose Aprepitant for Patients Receiving Carboplatin","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-10-30","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT01298193","phase":"PHASE4","title":"Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2011-05","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT00711555","phase":"PHASE2","title":"Emend for Multiple-day Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2005-11","conditions":"Nausea, Vomiting","enrollment":22},{"nctId":"NCT00588835","phase":"PHASE4","title":"Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2008-03","conditions":"Tumor","enrollment":20},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT03572829","phase":"PHASE2","title":"Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-03-01","conditions":"Vomiting, Nausea Post Chemotherapy, Head Neck Cancer","enrollment":44},{"nctId":"NCT03219710","phase":"PHASE3","title":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-07-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT01450826","phase":"PHASE2","title":"Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2014-06-24","conditions":"Nausea, Vomiting, Glioma","enrollment":136},{"nctId":"NCT00970905","phase":"PHASE2","title":"Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2009-10","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT00871910","phase":"PHASE1","title":"Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-11","conditions":"Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":81},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT00092183","phase":"PHASE4","title":"An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10-10","conditions":"Nausea, Vomiting, Breast Neoplasms","enrollment":866},{"nctId":"NCT00090207","phase":"PHASE4","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01-13","conditions":"Nausea, Vomiting","enrollment":477},{"nctId":"NCT00619359","phase":"PHASE3","title":"Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":2322},{"nctId":"NCT00734929","phase":"PHASE4","title":"Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-09","conditions":"Postoperative Nausea and Vomiting","enrollment":115},{"nctId":"NCT02979548","phase":"PHASE3","title":"Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy","status":"UNKNOWN","sponsor":"Dr Atul Sharma","startDate":"2016-11","conditions":"Chemotherapy Induced Vomiting, Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT01205503","phase":"PHASE2","title":"Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release","status":"COMPLETED","sponsor":"Mara Chambers","startDate":"2010-09","conditions":"Breast Cancer, Non-Hodgkin's Lymphoma","enrollment":32},{"nctId":"NCT00954941","phase":"PHASE2","title":"Ondansetron Versus Aprepitant Plus Ondansetron for Emesis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":100},{"nctId":"NCT01111851","phase":"PHASE1","title":"Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":16},{"nctId":"NCT01402024","phase":"PHASE3","title":"Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2011-08","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":96},{"nctId":"NCT00080444","phase":"PHASE3","title":"Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-04","conditions":"Vomiting","enrollment":50},{"nctId":"NCT02021851","phase":"PHASE4","title":"Prevention of Nausea and Vomiting in Patients After Surgery","status":"COMPLETED","sponsor":"Yeditepe University Hospital","startDate":"2011-07","conditions":"Postoperative Nausea and Vomiting","enrollment":67},{"nctId":"NCT01474915","phase":"PHASE4","title":"Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting","status":"COMPLETED","sponsor":"Sergio Bergese","startDate":"2007-06","conditions":"Postoperative Nausea and Vomiting (PONV), Nausea","enrollment":122},{"nctId":"NCT01897337","phase":"PHASE4","title":"The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-06","conditions":"Postoperative Nausea and Vomiting","enrollment":125},{"nctId":"NCT00651755","phase":"NA","title":"Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-03","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00314743","phase":"EARLY_PHASE1","title":"Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2005-10","conditions":"Nausea, Vomiting","enrollment":48},{"nctId":"NCT00499668","phase":"NA","title":"Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2007-08","conditions":"Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00659945","phase":"PHASE4","title":"Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-06","conditions":"Postoperative Nausea and Vomiting","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Emend"],"phase":"marketed","status":"active","brandName":"Aprepitant plus Ondansetron","genericName":"Aprepitant plus Ondansetron","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant blocks neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone while ondansetron blocks serotonin 5-HT3 receptors, together providing dual antiemetic coverage against chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy, Postoperative nausea and vomiting (PONV) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}